Brian Lee

Solo Angel Los Angeles, CA, United States

About Brian Lee

Brian Lee is co-founder of Honest Company, ShoeDazzle, and LegalZoom, currently at BAM Ventures in Los Angeles, writing $100k-$250k checks at pre-seed and seed in consumer wellness and digital health, with no AI flag. His operating credentials in consumer subscription, D2C, and mass-market consumer brands make him one of the most credentialed consumer-product angels in the LA ecosystem. Founders building consumer wellness products, D2C health and beauty, subscription-based digital health, or companies with mass-market consumer-brand ambitions are the natural fit and should treat him as a top-of-list target for the right consumer-led story. He is the wrong audience for biotech, devices, B2B healthcare software, AI-heavy plays, or anything requiring deep clinical expertise. The check size is meaningful, and a yes from him often pulls other quality LA consumer capital and brand-operator angels. Outreach via LinkedIn is viable, and BAM Ventures has a public website with deal-flow channels, but warm introductions through the LA consumer-product community, Honest Company alumni, or fellow consumer-subscription operators will materially outperform cold notes. Diligence will be sharply focused on unit economics, brand strategy, and customer acquisition; come with clear D2C metrics rather than vision-first narratives. Best for consumer wellness founders with strong brand instincts and credible early traction.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.
Portfolio data coming soon. Know their portfolio? Suggest an edit →
Team information coming soon. Know the partners? Suggest an edit →

Pitch / review this investor

Have you raised from Brian Lee? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.